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Background: The biological and clinical significance of multifocal and multicentric (MF/MC) breast cancers and the
choice of appropriate surgical treatment for these tumors are still debated.
Methods: 1158 women operated on for a stage I-III breast cancer were included in this retrospective study; clinical and
pathological data were obtained from the institutional database of the Department of Oncology of the University of
Siena, Italy. The impact of MF/MC breast cancers on patterns of recurrence and breast cancer specific survival (BCSS)
was investigated in relation to the type of surgical treatment.
Results: MF and MC cancers were present in 131 cases (11.3%) and 60 cases (5.2%) respectively and were more
frequently treated with mastectomy (55 MF and 60 MC cancers, 81.2%) than with breast conserving surgery (36 MF
cancers, 18.9%; p < 0.001). MF and MC breast cancers were associated with a worse prognosis with a BCSS of 154 months
compared to 204 months of unicentric cancers (p < 0.001). In multivariate analysis, MF/MC cancers were independent
prognostic factors for BCSS together with higher number of metastatic axillary nodes, absence of estrogen receptors and
high proliferative activity. MF and MC cancers were related to a significantly shorter BCSS in patients submitted to
mastectomy as well as those submitted to breast conserving surgery. Relapse at any site was higher in the subgroup of
MF and MC cancers but the incidence of loco-regional and distant recurrences did not differ between patients treated
with mastectomy or breast conserving surgery.
Conclusions: Our results indicate that MF/MC cancers have a negative impact on prognosis and are related to higher
loregional and distant relapse independently from the type of surgery performed. Adjuvant therapies did not modify the
poorer outcome, but in patients receiving adjuvant anthacyclines, the differences with unicentric tumors were reduced.
Our data support the hypothesis that MF/MC tumors may have a worse biological behavior and that the presence of
multiple foci should be considered in planning adjuvant treatments.
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The presence of multiple simultaneous foci of breast
cancer has been a well-known issue for decades [1], and
it was a deterrent for attempts to treat breast cancer
with non-mutilating procedures until the publication of
the first randomised trials of quadrantectomy and radio-
therapy [2-4].
Breast cancers are defined as multifocal when there is
more than one distinct tumour within the same quad-
rant of the breast (MF) and multicentric when multiple
cancers develop in different quadrants of the breast
(MC) [5]. MF/MC breast cancers have been reported
with an incidence of 40–70% in serial-sectioning studies
of mastectomy specimens [6-8], and are usually consid-
ered a contraindication to breast-conserving surgery [9]
because of an increased risk of local recurrence [10,11].
Indeed, breast-conserving surgery may be safely per-
formed in the case of MF/MC cancer provided that the
disease can be adequately excised with a good cosmetic
result [12].
The real incidence of MF/MC breast cancer is unclear,
as the presence of simultaneous cancers can be missed
either at preoperative evaluation by mammography and
ultrasound [13,14] or at pathological examination, unless
extensively searched with appropriate specimen analysis
techniques [15].
Breast magnetic resonance imaging (MRI) has been
shown to have a higher accuracy than conventional im-
aging in detecting MF/MC breast cancers [16]. Women
undergoing preoperative MRI have a significantly higher
proportion of MF/MC breast cancer diagnosed, and con-
sequently a higher number of mastectomies performed
[16,17]. This aggressive surgical approach could improve
the local control of disease and ultimately the survival,
as recent studies show a possible worse prognosis for pa-
tients with locoregional relapse after breast-conserving
surgery [18,19].
However, such a tendency towards a more extensive
surgery is debated. The COMICE trial did not show any
reduction of local recurrence or any improvement of
long-term survival in patients undergoing preoperative
MRI [17]. Moreover, the presence of occult MF/MC
breast cancer was a well-known issue when the first tri-
als of conservative surgery were conducted. The similar
survivals of patients treated with mastectomy or with
breast conservation and radiotherapy in those trials may
indicate that local control of the disease in the presence
of MF/MC disease can be obtained with less extensive
surgery without affecting long-term outcome [3]. As a
consequence, the recent increase of mastectomies re-
lated to MRI diagnosis of MF/MC cancers is not justi-
fied [20].
The controversy remains when considering the post-
surgical adjuvant treatments. In spite of the negativeprognostic significance of MF/MC cancers suggested in
early studies [8], the current edition of TNM stages
breast tumours using only the diameter of the largest
focus [21] and the presence of additional foci is not
taken into account in deciding adjuvant therapies.
Indeed, the biological and clinical significance of MF/
MC breast cancer is still controversial. In the literature,
few studies have investigated the prognosis of MF/MC
cancers, and they have produced contrasting results:
some investigators have not found any influence on
long-term survival [22-24] while other recent series have
reported a worse outcome for MF/MC breast cancers
[25,26].
Therefore, it remains unclear whether MF/MC breast
cancers should be considered a separate category with a
potentially unfavourable impact on prognosis and whether
these lesions require specific treatment with more exten-
sive surgery or committed adjuvant therapies.
The present study was directed to analyse, in a large
retrospective series of breast cancer patients treated at a
single institution, the impact of MF/MC breast cancers
on the long-term survival in relation to other known
pathological and clinical factors and to the type of treat-
ment received.
Methods
From January 1991 to December 2005, 1478 women af-
fected by breast cancer were operated on at the Depart-
ment of Oncology, Section of Surgical Oncology, University
of Siena, Italy. Clinical and pathological data of these pa-
tients were prospectively collected in an institutional com-
puterised database; this database was approved by the
Ethical Committee of the University Hospital of Siena and
the data were registered upon informed consent of the pa-
tients. For the purposes of the present study, the Scientific
Committee of the Department granted access to patient
data contained in the database. We selected those patients
without distant metastases at diagnosis that were submitted
to primary surgery and axillary lymph nodal dissection. Pa-
tients with synchronous bilateral breast cancers were ex-
cluded from the study.
Follow-up data were collected from our outpatient
clinic records, where the patients followed a standar-
dised program of clinical and instrumental examinations;
only patients with a follow-up of at least 36 months were
included in the study.
As a result, the study population included 1158 cases
of stage I–III breast cancers, with a median age of
63 years old (range 25–94) and 910 (78.6%) postmeno-
pausal women.
A mastectomy was performed in 631 (55.5%) patients
and a conservative surgery in 527 (44.5%); all patients
submitted to partial mastectomy received radiation ther-
apy on the residual breast with a boost on the tumour
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cancer, the primary surgical option was mastectomy, but
a conservative surgical approach was proposed when ad-
equate excision with acceptable cosmesis was possible.
All patients included in the study received an axillary
dissection of at least second level, with a mean number








Menopausal status Premenopausal 58
Postmenopausal 13







Tumor size 1a (0.1 – 0.5 cm) 5
1b (0.6 – 1 cm) 18
1c (1.1 – 2 cm) 74
2 (2.1 – 5 cm) 56
3 (>5 cm) 38




Tumor grade 1 40
2 10
3 51
Lymphovascular invasion* Absent 92
Present 88
Estrogen receptors* negative 76
positive. 10




Her-2/neu* not overexpressed 99
overexpressed 46
Number in parentheses are percentages; *missing cases: lymphovascular invasion 5An adjuvant systemic treatment was administered to
923 (79.7%) patients, with 445 women receiving chemo-
therapy and 478 endocrine therapy. Hormonal therapy
was adopted in 200 patients subsequent to chemotherapy.
Histopathological examination included: histological
type of cancer, as defined according to the WHO Work-
ing Group classification [27]; pathological tumour stage,icentric and multifocal/multicentric breast cancers
ultifocal/multicentric Unicentric p value






(23.4) 190 (76.6) p < 0.001
3 (14.6) 777 (85.4)
















(18.6) 175 (81.4) p = 0.45
0 (15.3) 553 (84.7)
(17.6) 239 (82.4)
(12.3) 654 (87.7) p < 0.001
(24.6) 269 (75.4)
(21.3) 280 (78.7) p = 0.006
5 (14.7) 611 (85.3)
(20) 252 (80) p = 0.08
8 (15.6) 636 (84.4)
(14.6) 432 (85.4) p = 0.4
(17.5) 461 (82.5)
(13.7) 625 (86.3) p = 0.019
(21.2) 171 (78.8)
5, Estrogen receptors 86, Progesteron receptors 89, Mib-1 93, Her2/neu 217.
Table 2 Factors independently related to multifocal/
multicentric breast cancers in multivariate analysis
(Logistic Regression)
RR 95% C.I. p
Age class <50 y.o. 1.66 1.099-2.51 0.016
Histotype Infiltrating lobular 2.92 1.33-6.38 0.007
Nodal status pN1 2.34 1.47-3.72 <0.001
pN2 2.23 1.26-3.94 0.006
pN3 8.67 4.84-15.52 <0.001
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ing to the criteria established by the TNM classification
[21]; grade of tumour evaluated according to the Scarff–
Bloom–Richardson classification modified by Elston and
Ellis [28]; and presence of peritumoural lymphovascular
invasion.
Estrogen receptors and progesterone receptors were
assessed by immunohistochemistry and tumours were
scored positive if at least 10% of tumour cells showed
nuclear staining. Proliferative activity was evaluated by
Ki-67 immunohistochemical assessment using a Mib-1
antibody; the cut-off value for high Mib-1 staining was




multifocal/multicentric breast cancer No 967
Yes 191
Tumor size 1a (0.1 – 0.5 cm) 53
1b (0.6 – 1 cm) 200
1c (1.1 – 2 cm) 484
2 (2.1 – 5 cm) 325





Tumor Grade G1 215
G2 653
G3 290
Lymphovascular invasion Absent 746
Present 357




*BCSS – breast cancer specific survival.maximised the separation of survival curves was 15% of
neoplastic cells staining [29]. Her-2/neu was evaluated
by immunohistochemistry giving a score range of 0–1+
(negative) to 3+ (positive); all 2+ scores were verified by
fluorescent in situ hybridisation.
Breast cancers were defined as multifocal (MF) if
there was more than one focus of invasive breast cancer
separated by benign tissue in the same quadrant, and
multicentric (MC) when distinct tumour foci were
found in different quadrants of the breast. Surgical
specimens were examined after slicing at 5-mm inter-
vals. Each tumour focus was identified macroscopically.
The surgical specimens were then fixed in 10% buffered
formalin and processed into paraffin blocks for histo-
pathological examination; normal tissue was confirmed
to be present between the various tumour foci. Hist-
ology was reviewed by TM and DT.
Correlations between clinicopathological variables and
MF and MC breast cancers were investigated by univariate
analysis and the chi-square test was used to assess their
statistical value; a p-value <0.05 was considered statistically
significant. As the correlations between MF or MC cancers
and clinicopathological variables were similar, these cases
were grouped together and a logistic regression model wasic survival in univariate analysis























Table 4 Prognostic value of multifocal and multicentric breast cancers according to tumor size and nodal status
5 year BCSS* 10 year BCSS*
Multifocal/multicentric Unicentric Multifocal/multicentric Unicentric
Tumor size 1a (0.1 - 05 cm) 100 100 80 100 p < 0.001
1b (0.6 – 1 cm) 86.9 97.6 74.5 87.5
1c (1.1 - 2 cm) 84 93.7 73.3 84.6
2 (2.1 - 5 cm) 77.2 87.1 67.7 75.5
3 (>5 cm) 63.5 71.7 48.4 58.7
Nodal status pN0 90.7 96 74.9 89.4 p 0.02
pN1 88.2 93.9 71.3 83
pN2 70.7 80.3 62.9 66.8
pN3 42 53.5 18.7 32.9
*BCSS – breast cancer specific survival.
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ciated with MF/MC cancers. Actuarial (Kaplan–Meier)
breast-cancer-specific survival (BCSS) was calculated from
the date of surgery. For the analysis of the events during
follow-up, recurrence of disease was classified as local
(breast or chest wall), regional (axillary, supraclavicular or
internal mammary lymph nodes) and distant. We evalu-
ated the prognostic significance of MF and MC breast can-
cers with respect to BCSS by means of a log-rank test. In
order to compare such prognostic significance to that of
the other clinical and pathological factors, a multivariate
analysis was performed by means of Cox regression ana-
lysis; the model of regression included those factors that
were significantly related to prognosis in univariate ana-
lysis. For statistical comparison, a p-value <0.05 was con-
sidered significant.
The Statistical Package for the Social Sciences software
(version 16.0) (SPSS, Chicago, Illinois, USA) was used
for statistical analysis.
Results
We found a multifocal breast cancer in 131 cases (11.3%)
and a multicentric breast cancer in 60 cases (5.2%). MF/
MC breast cancers were more frequently treated withTable 5 Multivariate Cox regression analysis for breast
cancers specific survival in the whole population
HR 95% C.I. p
multifocal/multicentric breast cancer present 1.64 1.05-2.57 0.029
Estrogen receptors absent 1.89 1.2-2.98 0.005
Mib-1 >15% 1.85 1.4-3.02 0.013
Nodal status pN0 1
pN1 1.73 0.87-3.22 0.116
pN2 3.08 1.53-6.16 0.002
pN3 9 4.95-16.4 <0.001mastectomy (55 MF and 60 MC cancers, 81.2%) than with
breast conserving surgery (36 MF cancers, 18.9%; p <
0.001). An adjuvant therapy was given in 79% (764 cases)
of unicentric cancers and in 83.2% (159 cases) of MF/MC
cancers (p = 0.138). Patients with MF/MC cancers more
frequently received chemotherapy (103 cases, 64.8%) than
hormone therapy (56 cases, 35.2%; p < 0.001), with a sig-
nificantly higher administration of anthracycline-based
regimens. The distribution of clinical and pathological fac-
tors in unifocal and MF/MC breast cancers is reported in
Table 1.
Multivariate analysis by means of logistic regression
indicated that age lower than 50 years old, lobular histo-
type and higher number of metastatic axillary nodes
were independently associated with MF/MC breast can-
cers (Table 2).
At a median follow-up of 88 months (range 11–248),
we observed 304 disease recurrences with a median time
to relapse of 32 months, and 172 patients died of breast
cancer. Actuarial BCSS was 89.7% at 5 years and 79.8%
at 10 years.
MF and MC breast cancers were associated with a
worse prognosis with a BCSS of 154 months (95% C.I.
139–169 months) compared to 204 months (95% C.I.
194–214 months) of unicentric cancers (p < 0.001).
Other clinical and pathological factors significantly asso-
ciated with prognosis in univariate analysis are reported
in Table 3.
The prognostic impact of MF/MC breast cancers was
confirmed when patients were stratified for tumour size
and number of metastatic axillary lymph nodes (Table 4).
In multivariate analysis, MF/MC cancers were inde-
pendent prognostic factors for poorer BCSS together
with higher number of metastatic axillary lymphnodes,
absence of oestrogen receptors and high proliferative
activity as expressed by Mib-1 staining (Table 5).
MF and MC cancers were related to a significantly
shorter BCSS in patients submitted to mastectomy as
Figure 1 Breast cancer specific survival in patients submitted to breast conserving surgery according to multifocality (Kaplan-Meier);
x unifocal cancers, • multifocal (MF) cancers.
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and 2).
In order to isolate the prognostic value of MF/MC breast
cancers in mastectomy patients and breast-conserving
surgery patients, a multivariate analysis was conducted in
the two subgroups separately. Clinical and prognostic pa-
rameters significantly related with prognosis in univariate
analysis were included in the regression model, and the
prognostic impact of MF/MC cancers was adjusted for age,
tumour size, nodal status, tumour grade, peritumoural
lymphovascular invasion, oestrogen receptor status and
Mib-1 expression. The results of this multivariate analysis
are reported in Table 6 and confirmed the independent
prognostic value of MF/MC breast cancers both in pa-
tients submitted to mastectomy and to breast-conserving
surgery.
The analysis of the sites of recurrence showed that re-
lapse at any site was significantly more frequent in pa-
tients with MF/MC breast cancers. Table 7 reports the
distribution of relapses in MF/MC breast cancers in rela-
tion to the type of surgery performed; the incidence of
locoregional and distant recurrences in MF/MC cancers
did not differ between cases treated with mastectomy or
with conservative surgery.A significantly negative impact of MF/MC breast cancers
on BCSS was present in patients who received an adjuvant
treatment (either chemotherapy or hormone therapy), and
in patients who did not receive any adjuvant treatment. A
similar trend was also found in the subgroup of patients
who received anthracycline-containing adjuvant therapy,
with a 10-year BCSS of 61.7% and 53.7% for unicentric and
MF/MC cancers respectively; however, this difference was
not statistically significant (p = 0.065).
Discussion
The reported incidence of MF/MC breast cancers in the
literature ranges from less than 10% to more than 60%
[8,24]; such variability depends either on different defini-
tions of multicentric and multifocal disease or on the
techniques of breast specimen sampling used.
The 16.9% incidence of MF/MC breast cancers in our
series is in line with data reported in other studies
[22-24,30,31] that applied routine protocols of breast
specimen sampling; a higher incidence of multiplicity is
reported in whole-breast sectioning studies, but these
techniques are usually reserved for research purposes
[6-8]. However, in our experience, breast-conserving sur-
gery was performed in almost half of the patients and
Figure 2 Breast cancer specific survival in patients submitted to mastectomy according to multifocality and multicentricity
(Kaplan-Meier); x unifocal cancers, • multifocal (MF), Δ multicentric (MC) cancers.
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MC as, in these cases, only the surgically removed quad-
rant was examined.
MF/MC cancers have been associated in the literature
with younger age [24], large tumour size [24], lobular
histotype [22,25,26], presence of peritumoural lympho-
vascular invasion [7,25], and higher incidence of axillary
nodal metastases [7,8,22,24-26,29]. Our study confirmsTable 6 Multivariate Cox regression analysis for breast cance
surgery
Breast conserving surgery multifocal/multicentric breast cancer
Mib-1
Nodal status
Mastectomy multifocal/multicentric breast cancer
Estrogen receptors
Nodal statusthe correlation between MF/MC breast cancers and
clinical-pathological factors suggestive of more aggres-
sive tumours, with the notable addition of the associ-
ation with the absence of ER and Her2-neu positive
status (Table 1). These relationships, particularly the
higher incidence of nodal metastases, may indicate a dif-
ferent biological behaviour of MF/MC cancers with an
increased propensity to disseminate, and consequently, ars specific survival in mastectomy and breast conserving
HR 95% C.I. p
yes 3.88 1.06-14.12 0.02
>15% 5.53 1.57-19.47 0.008
pN1 3.01 0.98-9.28 0.055
pN2 3.42 1.22-8.48 0.004
pN3 16.8 5.31-36.4 <0.001
yes 2.72 1.15-6.48 0.023
absent 2.3 1.36-3.87 0.002
pN1 1.56 0.68-3.59 0.28
pN2 4.73 2.24-9.9 <0.001
pN3 8.09 4.08-16.04 <0.001
Table 7 Sites of breast cancer recurrence according to the type of surgery and the presence of multifocal and
multicentric breast cancers
num. Local Regional Distant
Breast conserving surgery
unicentric 491 29 (5.9) p 0.32 8 (1.6) p 0.05 55 (11.2) p 0.03
multifocal/ multicentric 36 3 (8.3)* 2 (5.6)§ 7 (19.4)°
Mastectomy
unicentric 476 27 (5.7) p 0.11 18 (3.8) p 0.003 91 (19.1) p 0.011
multifocal/ multicentric 155 12 (7.7)* 11 (7.1)§ 42 (27.1)°
Total
unicentric 967 56 (5.8) p 0.05 26 (2.7) p 0.002 146 (15.1) p < 0.001
multifocal/ multicentric 191 15 (7.8) 13 (6.9) 49 (25.7)
Number in parentheses are percentages.
*Difference statistically not significant between breast conserving surgery and mastectomy for local recurrence (p 0.92).
§Difference statistically not significant between breast conserving surgery and mastectomy for regional recurrence (p 0.63).
°Difference statistically not significant between breast conserving surgery and mastectomy for distant recurrence (p 0.31).
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MF/MC breast cancers and their impact on prognosis are
still debated. Vlastos et al. [22] studied a series of 284
women submitted to mastectomy and adjuvant therapy
and did not find any prognostic value for MF/MC cancers,
interpreting the presence of multiple tumour foci and re-
lated nodal metastases as markers of chronological age ra-
ther than biological aggressiveness of the primary tumour.
The absence of prognostic significance of multiple foci of
breast cancer on survival was confirmed by Litton et al.
[23] in 300 young women aged less than 35 years old, and
in the review on 7024 cases from the Danish Breast Cancer
Group [24], where the significant association with a re-
duced disease free survival was explained by the increase
in local recurrence, which did not affect BCSS, in the
subgroup of patients with multifocal disease submitted to
conservative surgery.
Our study is based on the records of patients pro-
spectively collected in a dedicated database, and the de-
sign may then be considered similar to an observational
study. Moreover, follow-up has been conducted at our
outpatient clinic with an accurate prospective collection
of information on the sites of relapse, which are usually
not reported in other similar studies in the literature.
The majority of MF/MC cancers in our series were
treated by mastectomy. This is an issue common to
similar studies, because the presence of multiple foci
often excludes the possibility of breast-conserving sur-
gery and because pathological examination of the whole
breast allows discovery of a higher number of MF/MC
cancers. Even if we analysed the prognostic influence of
MF/MC cancers treated with mastectomy and conserva-
tive surgery separately, this aspect may be a limitation of
our study.
Our results indicate that MF/MC breast cancers have a
negative independent impact on BCSS, and this finding isin line with other recent papers. In the largest cohort of
25,320 patients reported in the literature, Yerushalmi et al.
[25] found an independent negative prognostic value of
MF/MC breast cancers on outcome, even if of low impact.
The same results were recently reported by Weissenba-
cher et al. [26] in a matched-pair analysis that included
288 pairs of unifocal vs. MF/MC breast cancers, which
demonstrated that multifocality and multicentricity were
independent predictors of reduced BCSS and increased
local relapse and distant metastases.
We investigated the prognostic impact of MF/MC
breast cancers in relation to the different types of breast
surgery performed. The negative prognostic impact of
MF/MC cancers on BCSS was present in both cases
treated with conservative surgery and with radical surgery.
MF cancers treated with conservative surgery had an ipsi-
lateral breast recurrence rate of 8.3%, higher than the rate
(5.9%) of unicentric cancers, but similar to the 7.7% inci-
dence of local recurrences of MF/MC cancers submitted
to mastectomy. MF/MC cancers were related to increased
locoregional and distant relapses independently from the
type of surgery performed, and the median BCSS for MF/
MC did not differ between patients treated with breast-
conserving surgery (177.4 months, 95% C.I. 150.3–204.5)
and with mastectomy (145.19 months, 95% C.I. 128.6–
161.7; p = 0.148). These findings are in accordance with
the hypothesis that a more aggressive surgical approach
does not improve either the locoregional control or the
distant outcome of MF/MC tumours [20].
When analysing BCSS with respect to adjuvant
chemotherapy, we found that neither hormone therapy
nor chemotherapy modified the poorer outcome of
MF/MC cancers; nonetheless, in patients receiving ad-
juvant anthracyclines, the differences in outcomes were
reduced and lost statistical significance. These results
are similar to those reported by Weissenbacher [26],
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in MF/MC cancers treated with hormone therapy and a
similar but not significant trend for cases treated with
chemotherapy.
Indeed, dividing our series on a chronological basis (5-
year periods of study), we found that the 10-year BCSS
varied from 83.8% for unifocal and 60.6% for MF/MC
breast cancers (p < 0.001) in the first period of study, to
91.5%, for unifocal and 84.5% for MF/MC (p = 0.035) in
the last period. This reduced difference over time may
be related to the increased number of patients with MF/
MC cancers submitted to adjuvant chemotherapy with
anthracyclines (from 16.9% in the first period to 42.2%
in the last period). This is in accordance with the study
of Vlastos [22], which suggests that adjuvant chemother-
apy, particularly the more intensive regimens including
anthracyclines, may be effective in reducing the negative
impact of multiplicity.
The current TNM classification considers only the di-
mension of the largest tumour focus, with a possible
underestimation of the higher tumour burden of MF/MC
cancers. Some authors have proposed that the aggregate
diameter of MF/MC tumours may be an effective estimate
of the tumour load [30] and should be considered when
planning the treatment of these patients, but these data
were not confirmed in other studies [31]. More detailed
analyses of tumour size using aggregate volumes of surface
areas showed that MF/MC breast cancers have a higher
incidence of nodal metastases than unicentric cancers of
similar volume [32]. These results support the hypothesis
that MF/MC breast cancers have a worse biological behav-
iour than unicentric tumours, independently from tumour
burden.
Conclusions
Despite the limitations of a retrospective study, our ex-
perience supports the hypothesis that MF/MC cancers
are biologically more aggressive than unifocal tumours,
have an increased propensity to metastatic diffusion and
are related to a worse outcome.
The analysis of the patterns of recurrence suggests
that breast conservation can be safely performed in MF
cancers, provided that an adequate excision is warranted,
and that more aggressive surgical approaches do not re-
sult in a better locoregional control or in reduction of
distant recurrences.
The increased aggressiveness of MF/MC breast cancers
may be faced with committed systemic adjuvant therapies;
as a consequence, we suggest that the presence of MF/MC
cancer should be considered in planning the adjuvant
treatments to convey the increased risk.
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